N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."
Chief Executive Nigel Theobald says: "2023 was a year of good progress for the company with material advancements in the capabilities of Nuvec both in its ability to dual load and in its potential for oral delivery. We achieved our objective of expanding our portfolio through our interest in Nanogenics which brings us a clear path for taking a product to market and the potential for orphan drug designation."
Current stock price: 0.82 pence, down 2.9% in London on Tuesday
12-month change: down 57%
By Sophie Rose, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
N4 Pharma Plc (N4P)